<DOC>
	<DOCNO>NCT00325429</DOCNO>
	<brief_summary>This study conduct United States . Vildagliptin oral antidiabetic agent . This 52-week clinical study design open label , long-term study aim evaluate safety vildagliptin patient type 2 diabetes .</brief_summary>
	<brief_title>Long-Term Safety Study Vildagliptin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosis type 2 diabetes Patients place diet exercise therapy without achieve target blood glucose level Outpatients Type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes Significant cardiovascular complication define protocol Significant diabetic complication define protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>HbA1c</keyword>
</DOC>